Elevated LDL-Cholesterol (LDL-C)

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Alnylam Pharmaceuticals
1 program
1
ALN-PCS02Phase 11 trial
Active Trials
NCT01437059Completed32Est. Sep 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alnylam PharmaceuticalsALN-PCS02

Clinical Trials (1)

Total enrollment: 32 patients across 1 trials

NCT01437059Alnylam PharmaceuticalsALN-PCS02

Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

Start: Sep 2011Est. completion: Sep 201232 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space